AI Upstart Manus Starts Text-to-Video Service to Take On OpenAI
The upstart, whose AI service is known for its ability to carry out multistep tasks the way humans do, said users can now similarly generate videos with text instructions. Its AI agent can transform a text command into a structured, sequenced video story in minutes, the company said on X.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
25 minutes ago
- Yahoo
3 Asian Growth Companies With High Insider Ownership Growing Earnings At 49%
Amid a backdrop of fluctuating global markets and evolving trade policies, Asian economies continue to demonstrate resilience, with China's export growth and Japan's strong corporate earnings providing positive signals. In such an environment, companies with high insider ownership often attract attention due to their potential for aligned interests between management and shareholders, making them appealing candidates for investors seeking growth opportunities. Top 10 Growth Companies With High Insider Ownership In Asia Name Insider Ownership Earnings Growth Zhejiang Leapmotor Technology (SEHK:9863) 15.6% 60.7% Vuno (KOSDAQ:A338220) 15.6% 109.8% Techwing (KOSDAQ:A089030) 19.1% 68% Suzhou Sunmun Technology (SZSE:300522) 35.4% 77.7% Shanghai Huace Navigation Technology (SZSE:300627) 24.3% 24.3% Novoray (SHSE:688300) 23.6% 28.2% M31 Technology (TPEX:6643) 30.8% 95.5% Laopu Gold (SEHK:6181) 35.5% 43% Gold Circuit Electronics (TWSE:2368) 31.4% 32.8% Fulin Precision (SZSE:300432) 12.8% 43.7% Click here to see the full list of 593 stocks from our Fast Growing Asian Companies With High Insider Ownership screener. Underneath we present a selection of stocks filtered out by our screen. ABL Bio Simply Wall St Growth Rating: ★★★★★☆ Overview: ABL Bio Inc. is a biotech research company specializing in developing therapeutic drugs for immuno-oncology and neurodegenerative diseases, with a market cap of ₩4.45 trillion. Operations: The company's revenue is primarily generated from its biotechnology startups segment, amounting to ₩27.63 billion. Insider Ownership: 26.6% Earnings Growth Forecast: 49.5% p.a. ABL Bio is poised for significant growth, with revenue expected to increase by 24.5% annually, outpacing the KR market's 7.3% growth rate. The company is forecast to become profitable within three years, although its future Return on Equity remains low at 0.1%. Recent engagements include presentations at the ESMO Gastrointestinal Cancers Congress and upcoming earnings calls aimed at elucidating R&D and management strategies, highlighting active leadership involvement in strategic communication. Take a closer look at ABL Bio's potential here in our earnings growth report. Upon reviewing our latest valuation report, ABL Bio's share price might be too optimistic. BYD Simply Wall St Growth Rating: ★★★★☆☆ Overview: BYD Company Limited, along with its subsidiaries, operates in the automobiles and batteries sectors across the People's Republic of China, Hong Kong, Macau, Taiwan, and internationally with a market cap of HK$1.06 trillion. Operations: The company's revenue segments include its operations in the automobiles and batteries sectors, generating income across China, Hong Kong, Macau, Taiwan, and international markets. Insider Ownership: 28.6% Earnings Growth Forecast: 15.9% p.a. BYD is experiencing robust growth, with earnings projected to increase by 15.9% annually, surpassing the Hong Kong market's average. The company's revenue is also expected to grow at 13.5% per year. Recent strategic moves include a dealership agreement in Finland and a partnership with FC Internazionale Milano, enhancing its global presence and aligning with its expansion strategy in Europe. Despite changes in capital structure, insider ownership remains significant, supporting long-term growth objectives. Unlock comprehensive insights into our analysis of BYD stock in this growth report. Insights from our recent valuation report point to the potential undervaluation of BYD shares in the market. China XLX Fertiliser Simply Wall St Growth Rating: ★★★★☆☆ Overview: China XLX Fertiliser Ltd. is an investment holding company involved in the development, manufacture, and sale of urea both in Mainland China and internationally, with a market cap of HK$10.51 billion. Operations: The company's revenue is primarily derived from the sale of urea (CN¥8.45 billion), methanol (CN¥5.98 billion), compound fertiliser (CN¥7.02 billion), DMF (CN¥1.19 billion), and melamine (CN¥0.93 billion). Insider Ownership: 17.9% Earnings Growth Forecast: 27.1% p.a. China XLX Fertiliser is poised for significant earnings growth, forecasted at 27.1% annually, outpacing the Hong Kong market. Despite a recent dip in net income to CNY 599.3 million for the first half of 2025, insider buying has been substantial over the past three months, indicating confidence in its growth trajectory. While trading at a favorable price-to-earnings ratio of 7x compared to peers, high debt levels remain a concern for investors. Click here and access our complete growth analysis report to understand the dynamics of China XLX Fertiliser. Our expertly prepared valuation report China XLX Fertiliser implies its share price may be lower than expected. Where To Now? Investigate our full lineup of 593 Fast Growing Asian Companies With High Insider Ownership right here. Contemplating Other Strategies? These 15 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years. Companies discussed in this article include KOSDAQ:A298380 SEHK:1211 and SEHK:1866. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Yahoo
25 minutes ago
- Yahoo
Why the latest inflation data gives investors a reason to smile
This post originally appeared in the Business Insider Today newsletter. You can sign up for Business Insider's daily newsletter here. Good morning. Ever considered investing in real estate? You might already have a big piece of what you need. "House hacking" is a new strategy homeowners are using to kick-start their rental portfolios. In today's big story, the latest inflation data gave investors a reason to feel upbeat about what's coming next. What's on deck: Markets: Why day traders' summer dominance could be hit with a September chill. Tech: Microsoft is dangling multimillion-dollar offers to poach Meta's AI talent. Business: Taylor Swift used to separate business from her love life. Not anymore. But first, the rally big story A best-case scenario Not too hot, not too cold — this was just right. The latest inflation report struck a good balance, delivering a best-case scenario for the stock market. The S&P 500 closed at a record high on Tuesday, while the Nasdaq rose over 1% and the Dow spiked nearly 500 points. US stock futures are continuing the climb this morning. The consumer price index rose 2.7% year-over-year in July, below economists' expectations of 2.8%. The figures may seem marginal, but for markets, this was the sweet spot. That's largely because it was likely low enough to allow the Federal Reserve to cut rates at its September meeting, BI's William Edwards writes. At the same time, the inflation reading was high enough to ease recession fears that had flared after the disappointing July jobs report, which included significant downward revisions to previous data. (The report rattled more than just economists — Trump promptly fired Bureau of Labor Statistics director Erika McEntarfer after the data was released.) Meanwhile, the latest inflation report opens up more positive possibilities. The CME FedWatch Tool now shows markets seeing 92% odds the Fed cuts rates by 25 basis points next month, up from about 80% on Monday. Higher odds are also now being priced in for cuts in October and December. For Trump, rate cuts can't come soon enough. "Jerome 'Too Late' Powell must NOW lower the rate. Steve 'Manouychin' really gave me a 'beauty' when he pushed this loser. The damage he has done by always being Too Late is incalculable." Writing in a Truth Social post early Tuesday, Trump said that he is also "considering allowing a major lawsuit against Powell to proceed" over the "grossly incompetent" job he's done renovating the Federal Reserve. This is the latest twist in Trump's feud with the Fed Chair, which seems to remain in an uncomfortable phase. The markets, at least, may be entering a brighter one. 3 things in markets 1. America's biggest bank is about to open its new headquarters. JPMorgan Chase's new 60-story skyscraper at 270 Park Avenue is full of high-end perks and amenities. The building includes a "state-of-the-art" gym — which the bank said employees will have to pay a membership fee to access — an Irish pub, AI tech systems, and more. Take a look. 2. A September showdown may be looming. Day traders outperformed professional money managers this summer, but their dominance might not last long. A historically seasonal pullback in retail trading and other headwinds threaten to upend the summer-long rally. 3. Trump's pick for Bureau of Labor Statistics chief suggested pausing US jobs reports. E.J. Antoni, Trump's nominee and chief economist at the Heritage Foundation, floated the idea on Fox News Digital earlier this month, citing accuracy concerns. Economists and market strategists told BI that such a move would be damaging for investors and economic planners. 3 things in tech 1. Microsoft has Meta AI talent in its sights. The software giant has a list of its most-wanted researchers and engineers from Meta and has already begun offering multimillion-dollar pay packages, documents viewed by BI's Ashley Stewart reveal. It's a step to compete with the eye-popping comp Microsoft's rivals are offering in the AI talent wars. 2. AI coding startups have an inference whale problem. Anthropic and Cursor are facing surging costs from a handful of heavy users, which is eating into their business models. As a result, they're introducing tiers or rate limits to what was formerly a basic fixed-price monthly subscription plan. 3. Baconator with a side of AI? Michael Chorey, the executive responsible for building out the AI automation for Wendy's drive-thru, which he says can take orders faster than a human in a headset, is leaving after five years. Chorey exclusively told BI that he is joining Presto, a tech company developing AI-first drive-thrus, which he believes is the next era of fast-food hospitality. 3 things in business 1. To solve the housing crisis, think outside the bounds. Outside the city bounds, that is. Ned Resnikoff argues that connecting cities, towns, and suburbs into large regional governances would make it easier and cheaper to buy a home in the US. Taxes from exclusive enclaves, like Greenwich, Connecticut, or Sausalito, California, would help support nearby cities. 2. Taylor Swift is in her boyfriend era. The pop star hard-launched the title of her newest album, "The Life of a Showgirl," in a teaser clip of her boyfriend Travis Kelce's podcast. It signals a shift in her marketing strategy, where she's putting her S.O. and her relationship front and center. 3. You've heard of quiet quitting, now get ready for quiet cracking. The latest threat to worker engagement is quiet cracking, in which people show up to work and do their jobs but still feel dissatisfied. Some of the warning signs can look like less extreme symptoms of burnout, EY's chief well-being officer told BI. In other news The DIY cage armor in Ukraine keeps getting weirder, wilder — and more 'Mad Max.' Spirit Airlines warns it may not survive another year after huge losses. A former Miss USA and Miss Teen USA thought the Miss Universe CEO's 'blond hair and blue eyes' comment was 'very destructive.' Elon Musk said Apple made it 'impossible' for non-ChatGPT AI apps to top the App Store. DeepSeek would like a word. Senate Democrats say a new crypto bill raises the risk of 'financial meltdown.' What's happening today Harvey Weinstein is sentenced in Manhattan after a jury convicted him on one count of sexual assault in a retrial. Hallam Bullock, senior editor, in London. Grace Lett, editor, in New York. Meghan Morris, bureau chief, in Singapore. Akin Oyedele, deputy editor, in New York. Amanda Yen, associate editor, in New York. Lisa Ryan, executive editor, in New York. Dan DeFrancesco, deputy editor and anchor, in New York (on parental leave). Read the original article on Business Insider Sign in to access your portfolio
Yahoo
25 minutes ago
- Yahoo
China pharma firms turn to local reagent suppliers to cut costs and delivery times
By Andrew Silver SHANGHAI (Reuters) -Pharmaceutical research and development firms in China are increasingly interested in procuring critical supplies known as reagents from local manufacturers, industry executives and managers said, as they seek to cut costs and delivery times. Western reagent suppliers including U.S.-based Thermo Fisher Scientific and Germany's Merck have profited in the world's second-largest pharmaceutical market from the compounds used in lab tests for analysis and quality control. But rising Chinese import tariffs due to the trade war with the U.S. and longer-term concerns about costs or access are spurring Chinese companies to request products from local rivals like Shanghai Titan Scientific and Nanjing Vazyme Biotech instead, the executives and managers said. The five who spoke to Reuters work at Chinese firms involved in the purchase or supply of reagents and their comments are an early sign of an expected industry shift toward more Chinese purchases. China's reagent market for lab and diagnostic use has been to some extent supplied by imports, which were valued at $5.76 billion in 2024, down slightly from $5.83 billion in 2023, according to U.N. Comtrade data. "It is actually more advantageous (for reagents to be local) because the timeliness requirement is high," said Ma Xingquan, co-president of pharmaceutical research firm ChemPartner PharmaTech. Most reagents it uses in its pre-clinical work are products that are made in China by firms including Titan and Shanghai Aladdin Biochemical Technology, he said. ChemPartner's usage of locally made reagents would probably increase further as new products become available, Ma added. TARIFF BUMP The rush to use domestically made reagents has accelerated since April, the month China raised duties on U.S. goods to 125%, a manager at Titan and an executive at Vazyme said, though the levies have since been lowered as Beijing and Washington continue trade talks. Some Chinese drugmakers were worried about tariff policy uncertainty, Titan product manager Yang Dong said. Since April, more than 90% of Vazyme's customers have discussed replacing imported reagents with its products, Vazyme Senior Vice President Xu Xiaoyu said. "Before April, customers were only saying long term, they hope to be able to replace (reagents) with those locally made, it would be better," Xu said. "But to customers these tariffs are like a shock in a short period of time. They clearly felt this type of direct impact... their impetus (for replacement) will be stronger." Titan and Vazyme are both forecast to report strong sales growth this year, according to brokers. China International Capital Corp expects Titan's annual revenue to grow 22% to 3.52 billion yuan ($490.39 million) this year, while Vazyme's revenue is set to rise 15% to 1.59 billion yuan over the same period, according to Soochow Securities. "There is still a lot of room for substitution of imported biological reagent enzymes, clients are strongly interested in locally-made replacements," Soochow said in a recent note. Shares in Titan and Vazyme have risen about 54% and 18% respectively since the start of the year. Merck and Thermo Fisher shares have fallen about 21% and 8% respectively over the same period. CHINA CHALLENGES Morningstar analyst Max Jousma expects China's reagents market to grow more than 10% annually over the next five years, driven by government support for the biotech and pharmaceutical sectors and growth in research and development activity and in-vitro diagnostic testing. Merck and Swiss diagnostics group Roche Holding are moving some of their reagent production closer to their Chinese customers. In 2023, Merck announced plans to invest 70 million euros ($81.35 million) in a reagents facility in Nantong that is on track to begin operations next year. Merck declined to comment on any short-term shifts in ordering patterns from Chinese customers. "The decision to invest in reagent manufacturing in Nantong reflects our commitment to supporting the growing needs of life science and biopharma customers in China and the broader Asia-Pacific region," it said in a statement. Roche is expanding production, laboratory and logistics facilities from 2028 in Suzhou, where it produces reagents for diagnostic systems, the company said in a statement. The expansion will help it meet increasing demand for diagnostic solutions in China and parts of Asia-Pacific, it said. Thermo Fisher declined to comment on its reagent sales and strategy to compete against local manufacturers in China, citing a policy of not providing details of its business by product line or country. Chinese drugmakers that use reagents from Western companies and are looking to purchase substitutes from local firms will face some challenges given the products are difficult to switch during or after the regulatory approval process because of a need for material consistency, industry experts said. "Switching reagents will cause significant disruption and delay for drug development," said Huang Linfeng, a scientist specialising in RNA biology at Duke Kunshan University. Another hurdle is manufacturer access to technology or processes, some of which could still be protected under patent or not disclosed, said Cheng Shaojun, a vice-general manager at supplier Fu Chen (Tianjin) Chemical Reagents Co. "(Reagent) production equipment is also not necessarily able to be bought," he added. ($1 = 0.8605 euros) ($1 = 7.1779 Chinese yuan renminbi)
